Yoshimura, Michio
Yamauchi, Chikako
Sanuki, Naoko
Hamamoto, Yasushi
Hirata, Kimiko
Kawamori, Jiro
Kawamura, Mariko
Ogita, Mami
Yamamoto, Yutaka
Iwata, Hiroji
Saji, Shigehira
Article History
Received: 13 November 2023
Accepted: 11 March 2024
First Online: 5 April 2024
Declarations
:
: MY, CY, NS, YH, KH, JK, MK, and MO have no conflict of interest. YY received research funding from Chugai, Kyowa-Kirin, Eisai, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Takeda, Eli Lilly, Pfizer, and Novartis, received honoraria from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Eli Lilly, Pfizer, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex, and Exact Science, participated on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Chugai, Novartis, MSD, Eli Lilly, Pfizer, and Daiichi-Sankyo, and is a member of the Board of Director of Japanese Breast Cancer Society and Japan Breast Cancer Research Group. HI received grants from Chugai, Daiichi Sankyo, and AstraZeneca, consulting fees from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, and Giliead, and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. SS received research funding from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo, received honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nippon Kayaku, participated on a Data Safety Monitoring Board or Advisory Board of Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD, is an executive member of JBCRG, JBCS, JSMO, and BIG.